Skip to main content
logo
Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
3.440
-0.090 (-2.55%)
Aug 14, 2026, 4:00 PM EDT - Market closed

Galectin Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-27.84-30.84-47.05-41.07-38.78-30.53
Depreciation & Amortization
0.060.050.040.030.030.04
Stock-Based Compensation
2.341.662.452.262.872.08
Other Operating Activities
5.314.640.511.13-0.150.15
Change in Accounts Payable
-2.99-6.04-2.072.674.243.69
Change in Other Net Operating Assets
7.246.654.362.010.720.27
Operating Cash Flow
-15.89-23.88-41.77-32.97-31.06-24.31
Operating Cash Flow Growth
------

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-2130301030
Net Debt Issued (Repaid)
102130301030
Issuance of Common Stock
5.395.481.2310.03-6.81
Financing Cash Flow
15.3926.4831.2340.031036.81

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-0.52.6-10.547.07-21.0612.51

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Levered Free Cash Flow
-14.86-20.9-29.31-20.68-17.56-13.23
Unlevered Free Cash Flow
-10.01-16.32-25.84-18.93-16.91-12.92

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
4.250.612.284.684.973.96
SEC Filings: 10-K · 10-Q